{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:06:46Z","timestamp":1792112806228,"version":"4.4.0"},"reference-count":49,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2004,1,5]],"date-time":"2004-01-05T00:00:00Z","timestamp":1073260800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2004,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>PURPOSE<\/jats:title><jats:p>This clinical trial is aimed at evaluating the impact of prostate cancer screening on cancer\u2010specific mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>SUBJECTS AND METHODS<\/jats:title><jats:p>Forty\u2010six thousand four hundred and eighty\u2010six (46,486) men aged 45\u201380 years registered in the electoral roll of the Quebec city area were randomized in 1988 between screening and no screening. Screening included measurement of serum prostatic specific antigen (PSA) using 3.0 ng\/ml as upper limit of normal and digital rectal examination (DRE) at first visit. At follow\u2010up visits, serum PSA only was used.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Seventy\u2010four (74) deaths from prostate cancer occurred in the 14,231 unscreened controls while 10 deaths were observed in the screened group of 7,348 men during the first 11 years following randomization. Median follow\u2010up of screened men was 7.93 years. A Cox proportional hazards model of the age at death from prostate cancer shows a 62% reduction (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.002, Fisher's exact test) of cause\u2010specific mortality in the screened men (<jats:italic>P<\/jats:italic>\u2009=\u20090.005). These results are in agreement with the continuous decrease of prostate cancer mortality observed in North America. \u00a9 2004 Wiley\u2010Liss, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pros.20017","type":"journal-article","created":{"date-parts":[[2004,3,23]],"date-time":"2004-03-23T13:39:04Z","timestamp":1080049144000},"page":"311-318","source":"Crossref","is-referenced-by-count":155,"title":["Screening decreases prostate cancer mortality: 11\u2010year follow\u2010up of the 1988 Quebec prospective randomized controlled trial"],"prefix":"10.1002","volume":"59","author":[{"given":"Fernand","family":"Labrie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Candas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Cusan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"B\u00e9langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Brousseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Chevrette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"L\u00e9vesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,1,5]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.53.1.5"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19990201)38:2<83::AID-PROS1>3.0.CO;2-B"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37402-5"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80419-1"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920701)70:1 <211::AID-CNCR2820701307>3.0.CO;2-D"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.179.1.2006303"},{"key":"e_1_2_1_8_2","first-page":"107","article-title":"Determination of prostate gland volume by transrectal ultrasound: Correlation with radical prostatectomy specimens","volume":"137","author":"Myschetzky PS","year":"1991","journal-title":"Scand J Urol Nephrol Suppl"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)38664-0"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.2307\/2288652"},{"key":"e_1_2_1_11_2","first-page":"719","article-title":"Statistical aspects of the analysis of data from restrospective studies of disease","volume":"22","author":"Mantel N","year":"1959","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_12_2","volume-title":"Statistical methods in cancer research, volume 1: The analysis of case\u2010control studies","author":"Breslow NE","year":"1980"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1994.03510290050036"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199104253241702"},{"key":"e_1_2_1_15_2","first-page":"425","article-title":"Optimized strategy for detection of early stage, curable prostate cancer: Role of prescreening with prostatic\u2010specific antigen","volume":"16","author":"Labrie F","year":"1993","journal-title":"Clin Invest Med"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1993.03510080052031"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/0090-4295(93)90233-Z"},{"key":"e_1_2_1_18_2","first-page":"461","article-title":"Adjuvant therapy after radical prostatectomy","volume":"4","author":"Brawer MK","year":"1990","journal-title":"Probl Urol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)37401-3"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0045(20000915)45:1<19::AID-PROS3>3.0.CO;2-M"},{"key":"e_1_2_1_21_2","first-page":"440","article-title":"Early detection of prostate cancer following repeated examinations by multiple modalities: Results of the American Cancer Society National Prostate Cancer Detection Project","volume":"16","author":"Mettlin C","year":"1993","journal-title":"Clin Invest Med"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2000.00679.x"},{"key":"e_1_2_1_23_2","first-page":"4","article-title":"Surveillance research, cancer facts and figures","author":"American Cancer Society","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"e_1_2_1_24_2","article-title":"Board of directors report: Early detection of prostate","author":"American Urological Association","year":"2001","journal-title":"American Urological Association"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.22.1683"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61941-4"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.23.1706"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)61628-8"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1148\/radiology.170.3.2644656"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707313370502"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.3.1013"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410X.1997.d01-6840.x"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199912093412401"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","unstructured":"HanksGE LuJ MachtayM VenkatesanV PinoverW ByhardtR et al.RTOG Protocol 92\u201002: A phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. In: 36th annual meeting of the American Society of Clinical Oncology; 2000 May 20\u201323; New Orleans LA USA;2000. p1284.","DOI":"10.1016\/S0360-3016(00)80021-8"},{"key":"e_1_2_1_36_2","first-page":"253","article-title":"Long\u2010term neoadjuvant and adjuvant combined androgen blockade is needed for efficacy of treatment in localized prostate cancer","volume":"1","author":"Labrie F","year":"1997","journal-title":"Mol Urol"},{"issue":"3","key":"e_1_2_1_37_2","first-page":"217","article-title":"Long\u2010term combined androgen blockade alone for localized prostate cancer","volume":"3","author":"Labrie F","year":"1999","journal-title":"Mol Urol"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(96)00513-5"},{"key":"e_1_2_1_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(94)80241-6"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80053-3"},{"key":"e_1_2_1_41_2","first-page":"351","article-title":"The economic burden of cancer","volume":"85","author":"Brown ML","year":"1993","journal-title":"J Natl Cancer Inst"},{"key":"e_1_2_1_42_2","first-page":"3","article-title":"Intracrinology and cancer therapy","volume":"5","author":"Labrie F","year":"1994","journal-title":"Science Watch"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.80.7.2002"},{"key":"e_1_2_1_44_2","first-page":"1","volume-title":"Cancer: Principle and practice of oncology","author":"Labrie F","year":"1999"},{"key":"e_1_2_1_45_2","first-page":"499","article-title":"Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial","volume":"16","author":"Labrie F","year":"1993","journal-title":"Clin Invest Med"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19941215)74:12<3146::AID-CNCR2820741214>3.0.CO;2-Z"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67074-5"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-4295(99)80055-7"},{"issue":"4","key":"e_1_2_1_49_2","first-page":"88","article-title":"Decrease in prostate cancer mortality following introduction of prostate specific antigen (PSA) screening in the federal state of Tyrol, Austria. AUA Annual Meeting","volume":"163","author":"Bartsch G","year":"2000","journal-title":"J. Urol"},{"key":"e_1_2_1_50_2","unstructured":"CandasB LabrieF.Unequal decrease of prostate cancer specific death rates through the Province of Quebec between 1991 and 1999. In: 14th Int. Symposium. J Steroid Biochem Mol Biol; 2000 June 24\u201327; Qu\u00e9bec Canada;2000. p133 Abstract 86\u2010P."}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpros.20017","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.20017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T15:50:03Z","timestamp":1700236203000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.20017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1,5]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,5,15]]}},"alternative-id":["10.1002\/pros.20017"],"URL":"https:\/\/doi.org\/10.1002\/pros.20017","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,1,5]]}}}